Share |
News

Verisante Pursues Listings on the OTCQX and Frankfurt Stock Exchange


May 9, 2011 at 2:00 pm

New listings would broaden access for American and European investors
interested in innovative device for the early detection of skin cancer


Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, PINKSHEETS: VRSEF) (the “Company” or “Verisante”) announced today that the Company is pursuing listings on both the OTCQX and the Frankfurt Stock Exchange (“FSE”).

Verisante is currently trading on the TSX Venture Exchange under the symbol VRS. Listing additionally on the OTCQX and the FSE would broaden the market to improve access to investors from both the United States and Germany.

“There are a growing number of American investors who are following Verisante Technology, and the Company would like to better serve those investors with the enriched trading platform provided through an OTCQX listing,” said Thomas Braun, President and CEO. “In addition, with European regulatory approval of our Verisante Aura™ device for skin cancer detection expected by the end of the year, listing on the Frankfurt Stock Exchange will give Verisante higher visibility among European investors.”

Verisante’s listings on the OTCQX and the FSE are expected to be completed by the third quarter of 2011.

About the OTCQX International

The OTCQX International is reserved for international companies listed on a qualified stock exchange in their home country and is the premier tier of the U.S. over-the-counter market.

OTCQX companies use the quality-controlled OTCQX platform to offer investors transparent trading, superior information, and easy access through their U.S. regulated broker-dealers. The innovative OTCQX platform offers companies and their shareholders a level of marketplace services formerly available only on a U.S. exchange. OTCQX provides the highest level of visibility and access to U.S. investors possible in the OTC Market.

About the Frankfurt Stock Exchange

The Frankfurt Stock Exchange was founded almost 400 years ago and today hosts companies from over 80 countries. It is one of the world's largest trading centres for securities.

The FSE accounts for over 90 percent of the turnover in the German market, a higher turnover velocity than the London exchange, and it is the largest of Germany's seven stock exchanges. It is also third in terms of volume, just behind New York and NASDAQ.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physician’s immediate diagnostic results for many of the most common cancers to assist in the biopsy decision.
 
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information contact:

Verisante Technology, Inc.
Thomas Braun, President & CEO
Telephone: (604) 605-0507

Email: info@verisante.com

Website: www.verisante.com

Youtube: www.youtube.com/verisante

Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top